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Abstract
Background: The mechanisms leading to virus-specific CD8+ T cell dysfuction in chronic hepatitis B virus (HBV)
infection remain to be elucidated. Our study focused on the role of transcription factor T-bet in HBV infection
because it is a crucial regulator of T cell immunity.
Methods: We assessed the expression of T-bet along with PD-1, IFN-γ and perforin, in HBV-specific CD8+ T cells
from resolved acute hepatitis B (rAHB) patients, chronic hepatitis B (CHB) patients, as well as asymptomatic HBV
carriers (ASCs). We observed dynamic changes of T-bet, PD-1, IFN-γ and perforin in acute stage and recovery stage
of acute hepatitis B (AHB).
Results: Comparing with other cohorts, HBV-specific CD8+ T cells from rAHB demonstrated a superior ability in
T-bet, IFN-γ and perforin expression, but an inferior ability in PD-1 expression. In the CHB group, the level of T-bet
has a linear relationship with the level of PD-1, IFN-γ and HBV DNA, respectively. A lower expression of T-bet and
PD-1 was observed in ASCs when compared with CHB. A higher expression of T-bet, PD-1, IFN-r and perforin was
observed in acute stage when compared with the recovery stage of AHB.
Conclusions: Our results suggest that expression of T-bet may influence the function of HBV-specific CD8+ T cells
and thus can be an attractive target for modulation to improve HBV-specific immunity in CHB.
Keywords: T-bet transcription factor, Hepatitis B virus, CD8 positive T lymphocytes
Background
Both the quantity and quality of the adaptive antiviral
immune response influence the clinical outcome of HBV
infection [1]. A multi-specific and vigorous T cell re-
sponse is present in acute hepatitis B (AHB) patients
who have successfully cleared HBV infection. However,
in chronic HBV infection including CHB and ASCs, the
T cell immune responses are weak and oligoclonal [2].
HBV-specific CD8+ T cells play important roles in clear-
ance of HBV infection and in the control of HBV repli-
cation [3]. A sustained and potent CD8+ T cell response
to HBV antigen is associated with resolved acute HBV
infection, but not with chronic HBV infection [4].
Chronic HBV infection acquired perinatally or in early
childhood is believed to progress through distinct
phases: immune tolerant, immune active and inactive
carrier. ASC means a patient is in immune tolerant
phase, while CHB means a patient is in immune active
phase [5]. The constant existence of viral antigens in-
trinsic in chronic infection may lead to loss of function
in antigen-specific T cells, decreased production of inter-
leukin- 2 (IL-2), tumor necrosis factor (TNF), interferon
gamma (IFN-γ) and chemotactic factor β, and gradually
impaired proliferation, decreasing cytotoxicity as well as
diminishing ability of T cell survival which eventually re-
sult in T cell exhaustion [6].
Immunoregulation is centrally involved in T cell ex-
haustion. These negative pathways can be grouped into
three main categories: cell surface inhibitory receptors
(such as PD-1), soluble factors (such as IL-10), and im-
munoregulatory cell types (such as regulatory T cells). In
addition, several specific transcriptional pathways have
been implicated in T cell exhaustion. Particularly, the
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transcription factor T-bet is centrally involved in CD8+
T cell exhaustion [7].
T-bet, which belongs to the T-box transcription fac-
tor family, is encoded by the Tbx21 gene and
expressed in many immune cells, showing an exten-
sive immunoregulatory function [8]. T-bet sustains
the effector function of CD8+ T cells through various
mechanisms, such as regulation of CD8+ T cell prolif-
eration, suppressed expression of inhibitory receptors
such as PD-1, and promotion of IFN-γ and perforin
secretion [9]. Dysfunction of CD8+ T cells has been
found in mice with defective Tbx21 and chronic in-
fection occurred after LCMV infection [10]. Chronic
HIV infection leads to decreased T-bet expression in
HIV-specific CD8+ T cells [11, 12]. Moreover, T-bet
has been implicated as an anti-tumor regulator and
pathogenic factor for autoimmune diseases [13, 14].
Currently, the correlation between the impaired regu-
lation of T-bet and the development of chronic HBV in-
fection has not been established. A study by Kurktschiev
PD et al. assessed the influence of T-bet on CD8 + T
cells activity observed during acute and chronic HBV in-
fection [15]. In our study, patients with HBV infection
were further divided into three groups: AHB, CHB and
ASCs. We have determined T-bet expression in these
groups and examined its correlation with the clinical
outcome. Our observations suggest a central role of T-




From May 2013 to December 2014, patients and con-
trols with positive human leukocyte antigen-A2 (HLA-
A2) from the Department of Infectious Diseases in the
First Affiliated Hospital of Harbin Medical University
(Harbin, China) or the Department of Infectious Dis-
eases in the Second Hospital of Daqing (Daqing, China)
were recruited for this study. Among these volunteers,
there were 9 AHB patients, 18 CHB patients, and 15
ASCs. The patient characteristics are summarized in
Table 1.
Diagnostic criteria
Subjects were selected according to previously described
criteria [16] as the following: AHB was defined as acute
onset of nonspecific flu-like symptoms and jaundice in
previously healthy persons with peak alanine amino-
transferase (ALT) elevation 10 times above the upper
limit of normal, and was confirmed by concomitant de-
tection of hepatitis B surface antigen (HBsAg), HBV
DNA, or anti-hepatitis B core IgM antibody (anti-HBc-
IgM). rAHB was confirmed by seroconversion of hepa-
titis B surface antibodies (anti-HBs). CHB was defined
by detection of HBV DNA or HBsAg for more than
6 months with ALT fluctuations. ASCs were defined as
HBsAg positive, ALT and aspartate aminotransferase
(AST) within the normal range for more than 3 visits,
and a history of HBV infection. Patients with other pos-
sible causes for chronic liver damage, such as alcohol
use, drug use, congestive heart failure and autoimmune
diseases, and pregnant women were also excluded from
this study.
Ethics statement
The experiments in this study were carried out under
the guidance of moral standards described in Declar-
ation of Helsinki and International Ethical Guidelines
for Biomedical Research Involving Human Subjects by
Council for International Organizations of Medical Sci-
ences (CIOMS), with the approval of ethics committee
in First Affiliated Hospital of Harbin Medical University
(approval ID: ChiCTR-CCC-14004949). An informed
consent was signed by all study subjects.
Table 1 Clinical characteristics of the three patient groups
AHB n = 9 CHB n = 18 ASCs n = 15 P values
Age (years, mean ± SD) 33.67 ± 5.32 42.45 ± 4.67 20.22 ± 3.71 <0.0001
Gender ( male/female) 5/4 10/8 8/7
HBsAg (+/−) 9/0 18/0 15/0
HBsAb (+/−) 1/8 0/18 0/15
HBeAg (+/−) 3/6 11/7 15/0
HBeAb (+/−) 8/1 7/11 0/15
HBcAb (+/−) 9/0 18/0 15/0
Median HBV DNA level (log10 IU/mL) 4.69(2.69–5.55) 5.31(2.26–8.58) 7.99(4.04–8.57) =0.0012
ALT (units/L)mean ± SD 1773.11 ± 1038.47 523 ± 775.40 19.43 ± 5.47 <0.0001
Abbreviations: AHB acute hepatitis B, CHB chronic hepatitis B, ASCs asymptomatic hepatitis B virus carriers, HBsAg hepatitis B virus surface antigen, HBsAb HBsAg
antibody, HBeAg hepatitis B e antigen, HBeAb HBeAg antibody, HBcAb hepatitis B core antibody, HBV DNA hepatitis B virus DNA, ALT alanine aminotransferase.
P values given as comparison among 3 groups by Kruskal-Wallis test
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Synthetic peptides, pentamers, and cytokines
Recombinant HBV core antigen (HBcAg) covering the
overall protein sequence of HBV genotype D was pur-
chased from ProSpec (NJ, USA). Human leukocyte anti-
gen (HLA) restricted peptide HBV core antigen 18–27
(FLPSDFFPSV and FLPSDFFPSI, HBV c 18–27) was pur-
chased from Proimmune (Oxford, UK). HBcAg and
HBV c 18–27 were used for the in vitro stimulation of
HBV-specific CD8+ T cells. HBV c 18–27 was detected
by PE-labeled MHC-I restricted pentamers (Proimmune,
Oxford, UK). Recombinant human IL-2 (PeproTech, NJ,
USA) was used for stimulation experiments.
Monoclonal antibodies for flow cytometry
FITC anti-human HLA-A2 (BioLegend, San Diego, CA,
USA), PE-Cy7 anti-human/mouse T-bet (eBioscience,
San Diego, CA, USA), APC anti-Human CD8a
(eBioscience, San Diego, CA, USA), FITC anti-human
CD279 (PD-1) (BioLegend, San Diego, CA, USA), PerCP
anti-CD14 (eBioscience, San Diego, CA, USA), APC-
eFluor®780 anti-CD19 (eBioscience, San Diego, CA,
USA) and 7-AAD (BD Biosciences, San Diego, CA,
USA) were used for flow cytometry. Isotype control was
used for each antibody. The Foxp3/Transcription Factor
Staining Buffer Set Kit (eBioscience, San Diego, CA,
USA) was used for intracellular staining according to the
manufacturer’s instructions.
HLA-A2 genotype detection
Screening for HLA-A2 was performed by staining per-
ipheral blood mononuclear cells (PBMCs) with a FITC-
labeled mouse anti-HLA-A 2 and isotype control (BD,
Biosciences, San Diego, CA, USA).
Isolation of PBMCs
PBMCs were isolated from fresh heparinized blood using
Ficoll-Hypaque density gradient centrifugation and were
either analyzed directly or resuspended in medium for
stimulation of PBMCs.
PBMC stimulation
For HBV-specific CD8+ T cells expansion, PBMCs were
cultured for 10 days in RPMI 1640 medium containing
2 mM l-glutamine, 1 mM sodium pyruvate, 100 U/ml of
penicillin, 100 μg/ml of streptomycin and 5 % human
type AB serum. PBMCs were seeded at a density of 1 ×
106/ml in 24-well plates, and 1 ml medium was used in
each well. In the cytokine-stimulated groups, IL-2
(20 IU/ml) was added on day 0. The antigen-stimulated
groups received 5 μg/ml of antigen on day 0 and were
re-stimulated with the same dose of antigen on day 10.
HBcAg (5ug/ml;) and HBV c 18–27 (FLPSDFFPSV, 5ug/ml;
FLPSDFFPSI, 5ug/ml) were used for stimulation. After
stimulation, cells were prepared for flow cytometry by cell
surface staining and intracellular staining [17].
Cell surface staining and intracellular staining for flow
cytometry
2–3 × 106 PBMCs were stained with MHC-I pentamers
according to the manufacturer’s instructions. After stain-
ing with viability dyes and antibodies specific for surface
markers, cells were fixed with intracellular fixation buf-
fer and permeabilized with permeabilization buffer. After
the permeabilization step, cells were stained with intra-
cellular markers. For ex vivo staining, at least 200,000
PBMCs were collected for pentamer + CD8+ T cells as
they were low frequency cells. Samples were acquired on
a FACSCanto II flow cytometer (BD, Biosciences, San
Diego, CA, USA). Data were analyzed with FlowJo 9.6.1
software (Tree Star). Gating strategy excluded mono-
cytes (CD14+), B-lymphocytes (CD19+), and dead cells
(7-AAD+) by a dump channel.
Enzyme-linked immunosorbent assay (ELISA)
PBMCs were cultured for HBV-specific CD8+ T cell ex-
pansion with stimulation by HBV antigen and peptides
for 10 days. Cells were then seeded into 96-well plates at
a density of 1 × 105 cells in 100 μl RPMI 1640 medium
in each well, and then stimulated again with HBV c 18–27
for 18 h. Subsequently, the cells and supernatant were col-
lected. A human IFN-γ embedded ELISA kit (Dakewe Bio-
tech, Beijing, China) and a human perforin embedded
ELISA kit (Dakewe Biotech) were used according to the
manufacturer’s instructions. Data were detected with a mi-
croplate reader and analyzed thereafter.
Statistical analysis
All data were analyzed using Prism 5.0 software (Graph-
Pad, CA, USA). Data were expressed as the median with
range or mean ± SEM. The Kruskal-Wallis Test was per-
formed to test the differences between the three groups,
and the difference of every two groups was tested using
the Mann–Whitney test (median) or t test (mean).
Spearman’s rank correlation test was used for correlation
analysis. P-values of P < 0.05 were considered significant.
Results
HBV-specific CD8+ T cell responses
Cell surface staining of PBMCs after in vitro induction
was carried out, and the percentage of HBV-specific
CD8+ T cells was analyzed by FACS for patients in the
rAHB, CHB or ASC groups respectively. The percentage
of HBV-specific CD8+ T cells in the total CD8+ T cells
of the rAHB, CHB and ASC group was 2.04 %, 1.14 %
and 0.46 %, respectively (P < 0.0001 by Kruskal-Wallis
test, Fig. 1).
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T-bet expression level in HBV-specific CD8+ T cells
The percentage of T-bet + cells in the total CD8+ T cells
of the rAHB , CHB and ASC groups was 41.21 %,
39.94 % and 31.42 %, respectively, with no significant
difference (P = 0.8619, by Kruskal-Wallis test, Fig. 2a).
As shown in Fig. 2b, the percentage of T-bet + cells in
the HBV-specific CD8+ T cells of the rAHB, CHB, and
ASC groups was 78.62 %, 52.67 % and 10.37 %, respect-
ively (P < 0.0001, by Kruskal-Wallis H test). The percent-
age in the rAHB group was higher than that in CHB
group (P < 0.01, by Wilcoxon test), while the latter was
higher than that in the ASC group (P < 0.01, by
Wilcoxon test).
PD-1 expression level in HBV-specific CD8+ T cells
The percentage of PD-1+ cells in the total CD8+ T cells of
the rAHB, CHB and ASCs was 6.79 %, 5.64 % and 7.75 %,
respectively, with no significant difference (P = 0.8099, by
Kruskal-Wallis test, Fig. 3a). The percentage of PD-1+ cells
in the HBV-specific CD8+ T cells of the rAHB, CHB and
ASC groups was 31.51 %, 50.68 % and 17.44 %, respectively,
with significant difference (P = 0.0013, by Kruskal-Wallis
test, Fig. 3b). The percentage in the rAHB group was lower
than that in the CHB group (P < 0.01, by Wilcoxon test).
The percentage in the CHB group was higher than that in
the ASC group (P < 0.01, by Wilcoxon test).
Induced IFN-γ and perforin levels in HBV-specific T cells
PBMCs isolated from the three groups were induced for
10 days with HBV antigens, followed by a further stimula-
tion with HBV antigens for 18 h. IFN-γ and perforin in the
supernatant were detected by ELISA. PHA-stimulated
(5ug/ml) samples were used as positive controls, and sam-
ples without antigen stimulation were used as negative con-
trols. Virus antigen stimulation resulted in similar IFN-γ
and perforin levels compared with that stimulated by PHA.
The IFN-γ levels in the AHB group were higher than those
in the CHB group (P < 0.0001, by unpaired t test) and those
in the ASC group (P < 0.0001 by unpaired t test). The IFN-
γ levels in the CHB group and the ASC group had no
significant differences (P = 0.2011, by unpaired t test). The
perforin levels in the rAHB group were higher than those
in the CHB group (P < 0.0001, by unpaired t test) and those
in the ASC group (P < 0.0001, by unpaired t test). The per-
forin levels in the CHB and ASC groups had no significant
difference (P = 0.1842, by unpaired t test, Fig. 4).
Relationships between T-bet, PD-1, IFN-γ and HBV DNA in
CHB
To further explore if T-bet can suppress PD-1 expression,
promote IFN-γ production and eventually affect serum
HBV DNA levels, we analyzed the correlation between
the percentage of T-bet + HBV specific CD8+ T cells
and PD-1+ HBV-specific CD8+ T cells, HBV DNA
load or IFN-γ level of the CHB patients. As shown in
Fig. 5, the percentage of T-bet + HBV-specific CD8+ T
cells showed a significant negative correlation to the per-
centage of PD-1+ HBV-specific CD8+ T cells (r =−0.8638,
P < 0.0001; Fig. 5a). The percentage of T-bet +HBV-specific
CD8+ T cells showed a significant negative correlation to
viral load of HBV (r = −0.8741, P < 0.0001; Fig. 5b). The
percentage of PD-1+ HBV-specific CD8+ T cells
showed a significant positive correlation to viral load
of HBV (r = 0.8864, P < 0.0001; Fig. 5c). The percentage
of T-bet +HBV-specific CD8+ T cells showed a significant
positive correlation to IFN-γ level (r = 0.7193, P = 0.0008;
Fig. 5d), The percentage of PD-1+ HBV-specific CD8+ T
cells showed a significant negative correlation to IFN-γ
level (r = −0.7027, P = 0.0011; Fig. 5e)
Dynamic changes of T-bet, PD-1, IFN-γ and perforin in
AHB
We further compared the percentage of T-bet + cells and
PD-1+ cells in the total HBV-specific CD8+ T cells, as
well as their capability for secretion of IFN-γ and per-
forin between the acute stage and recovery stage of the 7
AHB patients. Peripheral blood was collected when the
patients had been in hospital for 2 weeks, or had left
hospital for 16 weeks, respectively. The cells were in-
duced by antigens and each index was detected after a
10-day in vitro culture. As shown in Fig. 6, along with
Fig. 1 Percentage of pentamer + CD8+ T cells in the total CD8 + T
cells after in vitro induction. After induced amplification, peripheral
blood mononuclear cells (PBMCs) from patients with resolved acute
hepatitis B (rAHB), chronic hepatitis B (CHB) and asymptomatic
hepatitis B virus carriers (ASCs) were used to detect the percentage
of pentamer + CD8+ T cells in total CD8 + T cells. Each dot represents an
individual data point and the horizontal lines represent the mean
percentage of pentamer + CD8 T cells in the total CD8+ T cells
determined by flow cytometry. **represent P < 0.01,***represent
P < 0.001, by Mann Whitney test
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the recovery of disease, expression of T-bet, PD-1, IFN-γ
and perforin decreased 4 months after hospital discharge
accompanied by reduced percentage of HBV-specific
CD8+ T cells.
Discussion
The poor T-bet expression in virus-specific CD8+ T cells
may be a central regulation factor for T cell exhaustion
[7]. We compared in vitro amplification of HBV-specific
CD8+ T cells isolated from rAHB and CHB patients and
ASCs, under stimulation by viral antigens. Similar to
previous study [4], we found dysfunction and low re-
sponse of HBV-specific CD8+ T cells in the CHB pa-
tients and ASC patients comparing with those of rAHB
patients. The expression of T-bet in the HBV-specific
CD8+ T cells of CHB and ASCs were significantly lower
than those of rAHB patients. The T-bet expression was
lowest in the HBV-specific CD8+ T cells of ASCs. It has
been demonstrated that overexpression of T-bet can
promote T cell response, while suppression of T-bet ex-
pression can inhibit T cell response [18]. Our data
showed expression of T-bet was in accordance with
HBV specific CD8+ T cell response. Similar results con-
cerning T-bet expression were observed in HIV infected
patients [11]. Our data suggest that T-bet might regulate
the level of the HBV-specific CD8+ T cell response, and
low T-bet levels might be an important factor leading to
exhaustion of cytotoxic T cells in chronic hepatitis B. In
the CHB group, the level of T-bet had a negative correl-
ation with the level of HBV DNA, suggesting T-bet ex-
pression is vital for HBV clearance. The study by
Kurktschiev PD et al. compared T-bet expression be-
tween AHB and CHB [15]. Our study further showed
that the level of T-bet was lower in ASCs than in CHB.
We propose that lower expression of T-bet may be a fac-
tor of immune tolerance and higher expression of T-bet
may trigger a biological process leading to loss of im-
mune tolerance.
The axis of PD-1 and its ligand is a major inhibitory
receptor pathway involved in CD8+ T cell exhaustion
[7], and PD-1 can be suppressed by T-bet in chronic
murine LCMV infection [9]. IL-12 can induce T-bet and
Fig. 2 T-bet expression in HBV-specific CD8+ T cells. a Percentage of T-bet + cells in the total CD8+ T cell population (CD8 + T-bet+/CD8+) deter-
mined by flow cytometry. Data are shown as median (IQR). IQR = interquartile range. P > 0.05, by Kruskal-Wallis H test. b Percentage of T-bet +
cells in HBV-specific CD8+ T cells (pentamer + CD8 + T-bet+/pentamer + CD8+) determined by flow cytometry. Data are shown as median (IQR).
IQR = interquartile range. **represent P < 0.01,***represent P < 0.001, by Mann Whitney test. c Representative flow cytometry data of T-bet
expression
Fan et al. Virology Journal  (2016) 13:14 Page 5 of 10
decrease PD-1 expression level in chronic hepatitis B
and restore IFN production [19]. In our study, PD-1 ex-
pression was higher in the HBV-specific CD8+ T cells of
CHB patients comparing with those of rAHB patients,
and a higher PD-1 expression was coexisting with a
lower HBV-specific CD8 + T cell response. The PD-1 ex-
pression level was positively correlating with the level of
HBV DNA in CHB patients. This suggests that PD-1/PD-
L1 pathway may inhibit HBV clearance by inhibiting HBV-
specific CD8+ T cells. A similar PD-1 expression was ob-
served in HIV infected patients [20]. It was noted that the
PD-1 expression was lower in the ASC group than in the
CHB group. One reason is that ASC patients is in immune
tolerant phase, and PD-1 expression is lower in immune
Fig. 3 PD-1 expression in the HBV-specific CD8+ T cells. a Percentage of PD-1+ cells in total CD8+ T cells (CD8 + PD-1+/CD8+) determined by
flow cytometry. Data are shown as median (IQR). IQR = interquartile range. P > 0.05, by Kruskal-Wallis H test. b Percentage of PD-1+ cells in the
HBV-specific CD8+ T cell population (pentamer + CD8 + PD-1+/pentamer + CD8+) determined by flow cytometry. Data are shown as median
(IQR). IQR = interquartile range. ns represent no significant, **represent P < 0.01, ***represent P < 0.001, by Mann Whitney test. c Representative
flow cytometry data of PD-1 expression
Fig. 4 IFN-γ and perforin levels in the HBV-specific CD8+ T cell population. a Mean level of IFN-γ produced by HBV-specific T cells. Error bars
indicate SEM. b Mean level of Perforin levels produced by HBV-specific T cells. Error bars indicate SEM. *represents P < 0.05, **represents P < 0.01,
***represents P < 0.001, ns means no significant, by unpaired t test
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tolerant phase than in immune active phase [21]. Another
reason is that the ASC patients we chose were younger
than the CHB patients, and PD-1 expression is lower in the
young adult patients than in the older cohort from chronic
HBV infected patients [22].
As a ‘master regulator’ of cell-mediated immunity, T-
bet participates in regulation of genes encoding effector
molecules in immune cells, such as IFN-γ, perforin, and
granzymes [23]. CD8+ T cells participate in clearance of
intracellular viruses upon production of IFN-γ, and can
lyse target cells with perforin and granzymes [24]. We
observed a high level expression of IFN-γ and perforin
in the rAHB group and a low level expression of these
genes in the CHB and ASC groups, with a positive cor-
relation between T-bet and IFN-γ production in the
CHB group. These results indicate that low T-bet ex-
pression in chronic HBV infection might lead to
impaired production of IFN-γ and perforin. Because the
transcription factor eomesodermin also controls produc-
tion of IFN-γ and peforin in effector CD8 + T cells, fur-
ther studies of the roles of eomesodermin in chronic
HBV infection is necessary [25].
We followed up the AHB patients to determine differ-
ences in the acute stage and recovery stage of AHB. Our
results showed that both T-bet and PD-1 had higher
levels along with IFN-γ and perforin in the acute stage
than in the recovery stage. A previous study also indi-
cated that at clinical onset of acute HBV infection, PD-1
was significantly up-regulated and subsequently led to
the functional suppression of HBV-specific CD8+ T
cells, and that following disease resolution, HBV-specific
effector CD8+ T cells developed into memory T cells.
During this period, the dynamic PD-1 decrease was nu-
merically correlated with the reduction of HBV-specific
Fig. 5 Correlation between percentage of T-bet + or PD-1+ HBV-specific CD8+ T cells and HBV DNA content or IFN-γ level in PBMC from CHB
patients. a The percentage of T-bet + cells was negatively related to the percentage of PD-1+ cells (r = −0.8638, p < 0.0001); b The percentage of
T-bet + cells was negatively related to HBV DNA (r = −0.8741, p < 0.0001); c The percentage of PD-1+ cells was positively related to HBV DNA
(r = 0.8864, p < 0.0001); d The percentage of T-bet + cells was positively related to IFN-γ level (r = 0.7193, p = 0.0008); e The percentage of PD-1+
cells was negatively related to IFN-γ level (r = −0.7027, p = 0.0011), Spearman rank correlation test was used for data analysis
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CD8+ T cell frequency [26]. Another study showed that
the effect of T-bet on PD-1 expression was modest dur-
ing acute infection but became greater during chronic
infection [9]. We propose that in the acute stage, a high
level of T-bet expression can promote amplification of
CD8+ T cells and result in virus clearance, and that a
high level of PD-1 might lead to rapid apoptosis of
effector cells. So, the balance between T-bet and PD-1 in
the acute phase is critical to virus clearance and patho-
logical damage control.
Concerning the potential mechanism underlying low
expression of T-bet in virus specific CD8+ T cells in pa-
tients with chronic HBV infection, Smith et al. suggested
that during constant infection, antigen presenting cells
Fig. 6 Changes of HBV-specific CD8+ T cells, T-bet, PD-1, IFN-γand perforin in AHB. a Percentage of HBV-specific CD8+ T cells existed in the acute
and recovery stages (p = 0.0343, by Wilcoxon signed rank test); b Level of T-bet in HBV-specific CD8+ T cells in the acute and recovery stages
(p = 0.0156, by Wilcoxon signed rank test); c Level of PD-1 in HBV-specific CD8+ T cells in the acute and recovery stages (P = 0.0313, by Wilcoxon
signed rank test); d Level of IFN-γ in HBV-specific CD8+ T cells in the acute and recovery stages (P = 0.0006, by paired t test); e Level of perforin in
HBV-specific CD8+ T cells in the acute and recovery stages (P = 0.0062, by paired t test); f Representative flow cytometry data of T-bet and PD-1
expression in acute stage and recovery stage of AHB
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might influence the transcription of transcription factors
in virus specific T cells, such as T-bet [27]. EJ Wherry et
al. suggested that constant virus infection led to a con-
tinuous conversion from T-bethigh progenitor cells to
Eomeshigh cells in virus specific CD8+ T cells, which
eventually led to the disappearance of T-bethigh cells
[28]. Previous studies have shown that inflammatory sig-
nals (e.g., IL-12) not only enhance T-bet expression but
may also repress Eomes and thus play a dominant role
in regulating memory/effector T-cell potential [29]. The
IL-21–induced cytotoxic T cell (CTL) function is T-bet
dependent, because T-bet deficiency results in defective
IL-21–dependent cytotoxicity in CD8+ T cells in vitro
and in vivo [30]. Therefore, it is possible that lack of IL-
12 or IL-21 results in low T-bet expression in chronic
hepatitis B.
Conclusion
The expression of T-bet is closely related to exhaustion
of T cells in chronic hepatitis B, and T-bet might be a
critical factor leading to chronic HBV infection. Further
understanding of T-bet function may provide new thera-
peutic approaches for chronic hepatitis B. We observed
different levels of T-bet and PD-1 expression between
CHB and ASC patients, and these may explain the dif-
ferent immune status during chronic HBV infection.
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